Medline Inc. (MDLN)
| Market Cap | 48.17B |
| Revenue (ttm) | 29.14B +12.1% |
| Net Income | 966.00M -21.4% |
| EPS | 1.14 |
| Shares Out | 1.31B |
| PE Ratio | 32.11 |
| Forward PE | 23.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,034,140 |
| Open | 35.84 |
| Previous Close | 35.84 |
| Day's Range | 35.44 - 36.80 |
| 52-Week Range | 34.89 - 50.88 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 51.42 (+40.22%) |
| Earnings Date | May 6, 2026 |
About MDLN
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam g... [Read more]
Financial Performance
In 2025, Medline's revenue was $28.43 billion, an increase of 11.47% compared to the previous year's $25.51 billion. Earnings were $1.16 billion, a decrease of -3.42%.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for MDLN stock is "Buy." The 12-month stock price target is $51.42, which is an increase of 40.22% from the latest price.
News
Medline announces participation in upcoming investor conferences
NORTHFIELD, Ill., May 27, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that members of the executive leadership team will be participating in the following investor...
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue ...
Medline 72.6M share Secondary priced at $37.00
The deal size was increased to 72.6M shares of common stock from 60M shares of common stock. Goldman Sachs, Morgan Stanley, BofA and JPMorgan acted as joint book running managers…
Medline Inc. announces pricing of upsized secondary offering of Class A common stock
NORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.'s Class A ...
Medline expands animal health portfolio with spay/neuter surgical packs
Ready-to-use packs help reduce prep time and improve inventory management, allowing organizations to focus more on patient care NORTHFIELD, Ill., May 20, 2026 /PRNewswire/ -- Medline (Nasdaq: MDLN) an...
Medline Registration statement: Registration filing
Medline filed a registration statement on May 20, 2026, providing details about a securities offering with the SEC.
Medline files to sell 60M shares of Class A common stock for holders
Medline (MDLN) announced that certain selling stockholders affiliated with Blackstone, Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority, have commenced an und...
Medline Inc. announces launch of secondary offering of Class A common stock
NORTHFIELD, Ill., May 20, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and...
Medline files to sell 60M shares of Class A common stock for holders
07:03 EDT Medline (MDLN) files to sell 60M shares of Class A common stock for holders
Medline deploys new AutoStore installation at distribution center in Aurora, Colorado
NORTHFIELD Ill., May 18, 2026 /PRNewswire/ -- Medline (Nasdaq: MDLN) has unveiled a new AutoStore™ installation at its distribution center in Aurora, Colo.
Tigress Financial ups Medline price target, sees buying opportunity
Tigress Financial raised the firm’s price target on Medline (MDLN) to $62 from $60 and keeps a Buy rating on the shares, arguing that the company’s the ongoing transition from…
Medline price target lowered to $42 from $48 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Medline (MDLN) to $42 from $48 and keeps a Hold rating on the shares.
Medline price target lowered to $54 from $56 at Bernstein
Bernstein lowered the firm’s price target on Medline (MDLN) to $54 from $56 and keeps an Outperform rating on the shares following quarterly results. The firm notes that companies are…
Medline price target lowered to $55 from $60 at Citi
Citi analyst Patrick Donnelly lowered the firm’s price target on Medline (MDLN) to $55 from $60 and keeps a Buy rating on the shares. The firm reduced estimates post the…
Medline reports Q1 adjusted EPS 33c, consensus 29c
Reports Q1 revenue $7.35B, consensus $7.16B. “We started 2026 with strong momentum-growing with our existing customers, executing implementations at scale and winning new customers,” said Jim Boyle, c...
Medline backs FY26 adjusted EBITDA view $3.5B-$3.6B
Raises FY26 organic sales view to 8.5%-9.5% from 8%-9%.
Medline issued recall of all neuro sponge products, FDA says
The FDA said in a letter to healthcare providers that on March 13, Medline (MDLN) issued a customer letter stating higher than expected endotoxin levels have been identified on Medline…
Medline Earnings Call Transcript: Q1 2026
Q1 2026 saw 11% sales growth, driven by strong Supply Chain Solutions and new customer wins, but adjusted EBITDA fell 11% due to higher costs and tariffs. Full-year organic sales guidance was raised to 8.5%-9.5%, while EBITDA guidance remains unchanged, balancing tariff relief with operational investments and inflationary headwinds.
Medline Earnings release: Q1 2026
Medline released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Medline Slides: Q1 2026
Medline has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Medline Quarterly report: Q1 2026
Medline has published its Q1 2026 quarterly earnings report on May 6, 2026.
Medline Reports First Quarter 2026 Results
Net sales of $7.4 billion, an increase of 10.7% Net income of $239 million, a decrease of 25.8% Adjusted EBITDA 1 of $776 million, a decrease of 10.6% Raising full year 2026 Organic Sales 2 guidance r...
Medline share weakness overdone, ‘misinterpretation’-driven, says Leerink
The decline in Medline (MDLN) shares appears overdone and likely driven by a misinterpretation of an FDA-related headline, as the affected products are tied to a third-party supplier and have…
FDA revokes approval for several Medline products
The FDA has revoked approval for several Medline (MDLN) products, the agency said on its website.
Medline Proxy statement: Proxy filing
Medline filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.